canakinumab

Novartis bid to repurpose rare disease drug for cancer falls short in third trial
Novartis bid to repurpose rare disease drug for cancer falls short in third trial
BioPharma Dive
Novartis
cancer
clinical trials
lung cancer
canakinumab
Flag link:
Novartis hits another setback in plan to repurpose rare disease drug in lung cancer
Novartis hits another setback in plan to repurpose rare disease drug in lung cancer
BioPharma Dive
Novartis
clinical trials
canakinumab
Ilaris
lung cancer
Flag link:
Novartis’ Autoimmune Drug Not Up for the Challenge in Phase III Cancer Trial
Novartis’ Autoimmune Drug Not Up for the Challenge in Phase III Cancer Trial
BioSpace
Novartis
canakinumab
clinical trials
metastatic non-small cell lung cancer
Flag link:
Setback for Novartis drug in advanced lung cancer trial
Setback for Novartis drug in advanced lung cancer trial
Biopharma Reporter
Novartis
clinical trials
canakinumab
metastatic non-small cell lung cancer
Flag link:
Novartis’s canakinumab cancer test approaches
Novartis’s canakinumab cancer test approaches
EP Vantage
Novartis
Regeneron
canakinumab
cancer
non-small cell lung cancer
Flag link:
Novartis to begin trial with canakinumab in COVID-19 pneumonia patients
Novartis to begin trial with canakinumab in COVID-19 pneumonia patients
Pharmaceutical Business Review
Novartis
COVID-19
pneumonia
clinical trials
canakinumab
Flag link:
ACC: Novartis' canakinumab cuts CV risks in patients with kidney disease, diabetes by up to 18%
ACC: Novartis' canakinumab cuts CV risks in patients with kidney disease, diabetes by up to 18%
Fierce Pharma
Novartis
canakinumab
kidney disease
ACC
Flag link:
Prepping a case for canakinumab, Novartis tries to stake out a high-value segment of huge cardio market
Prepping a case for canakinumab, Novartis tries to stake out a high-value segment of huge cardio market
Endpoints
Novartis
canakinumab
heart disease
heart attack
Flag link:
Novartis shares slip after mixed heart drug data
Novartis shares slip after mixed heart drug data
Yahoo/Reuters
Novartis
canakinumab
Ilaris
cardiovascular disease
Flag link:
Drugmakers face challenges marketing new heart drugs
Drugmakers face challenges marketing new heart drugs
Medical Marketing and Media
drug marketing
Amgen
Repatha
Novartis
Entresto
Ilaris
canakinumab
Merck
Anacetrapib
Flag link:
Details on surprise Novartis heart drug success due Aug 27
Details on surprise Novartis heart drug success due Aug 27
Yahoo/Reuters
Novartis
canakinumab
heart attacks
stroke
Flag link: